Security Snapshot

Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) Institutional Ownership

CUSIP: 05280R100

13F Institutional Holders and Ownership History from Q2 2018 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

84

Shares (Excl. Options)

134,436,091

Price

$1.38

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share
Symbol
AUTL on Nasdaq
Shares outstanding
266,837,198
Price per share
$1.41
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
134,436,091
Total reported value
$184,354,727
% of total 13F portfolios
0%
Share change
-3,613,694
Value change
-$5,299,819
Number of holders
84
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Key facts

  • AUTL - Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share is tracked under CUSIP 05280R100.
  • 84 institutions reported positions in Q1 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 90 to 84 between Q4 2025 and Q1 2026.
  • Reported value moved from $277,117,628 to $184,354,727.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 84 institutions filings for Q1 2026.

Open SEC Evidence

Security key

05280R100

Latest holder period

Q1 2026

13F holders

84

13D/G owners

5

CIK / CUSIP context first

Open Q1 2026 holders AUTL full holder history Autolus Therapeutics plc SEC filings Autolus Therapeutics plc company facts Autolus Therapeutics plc insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Significant Owners of Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MAK Capital Fund LP 13% +12% $49,423,586 +$5,315,732 33,621,487 +12% MAK Capital Fund LP 31 Mar 2026
Syncona Portfolio Ltd 11% $37,755,579 28,821,053 Syncona Portfolio Limited 31 Mar 2025
ARMISTICE CAPITAL, LLC 5.9% -9.1% $23,226,000 -$2,499,000 15,800,000 -9.7% Armistice Capital, LLC 31 Mar 2026
FMR LLC 3.8% $13,312,676 10,162,348 FMR LLC 31 Mar 2025
Deep Track Capital, LP 0.97% $4,186,839 2,568,613 Deep Track Capital, LP 30 Sep 2025

As of 31 Mar 2026, 84 institutional investors reported holding 134,436,091 shares of Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL). This represents 50% of the company’s total 266,837,198 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) together control 49% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
MAK CAPITAL ONE LLC 13% 33,621,487 +12% 7.7% $46,397,652
Blackstone Inc. 7.7% 20,485,611 0% 0.12% $28,270,143
Syncona Portfolio Ltd 6.2% 16,640,720 0% 89% $22,964,194
ARMISTICE CAPITAL, LLC 5.9% 15,800,000 -9.7% 0.72% $21,804,000
Tetragon Partners GP Ltd 3.6% 9,500,000 0% 2.6% $13,110,000
SCHRODER INVESTMENT MANAGEMENT GROUP 3.6% 9,489,345 0% 0.01% $12,051,468
Frazier Life Sciences Management, L.P. 1.7% 4,447,910 -3.8% 0.16% $6,138,116
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.3% 3,361,156 0% 0.01% $4,638,395
Laurion Capital Management LP 1.2% 3,316,626 0% 0.43% $4,576,944
RENAISSANCE TECHNOLOGIES LLC 0.86% 2,299,499 -26% 0% $3,173,309
BANK OF AMERICA CORP /DE/ 0.69% 1,844,671 -5.9% 0% $2,545,646
BlackRock, Inc. 0.55% 1,480,732 -60% 0% $2,043,410
UBS Group AG 0.49% 1,305,779 +49% 0% $1,801,976
Cetera Investment Advisers 0.42% 1,129,074 +2.7% 0% $1,558,122
Balyasny Asset Management L.P. 0.36% 971,691 0% $1,340,934
MORGAN STANLEY 0.35% 941,823 -33% 0% $1,299,716
JPMORGAN CHASE & CO 0.35% 935,403 -4.5% 0% $1,187,962
Alphabet Inc. 0.26% 698,262 0% 0.02% $963,602
Marex Group plc 0.2% 542,857 0.01% $749,143
CITADEL ADVISORS LLC 0.17% 459,404 -60% 0% $633,978
Hennion & Walsh Asset Management, Inc. 0.16% 440,206 -3% 0.02% $607,484
Point72 Asset Management, L.P. 0.16% 426,983 +40% 0% $589,237
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.15% 399,143 -33% 0% $550,817
Privium Fund Management B.V. 0.14% 363,430 +11% 0.1% $501,533
EDENTREE ASSET MANAGEMENT Ltd 0.11% 300,000 0% 0.13% $414,000

Institutional Holders of Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 134,436,091 $184,354,727 -$5,299,819 $1.38 84
2025 Q4 139,369,843 $277,117,628 -$1,857,316 $1.99 90
2025 Q3 143,579,673 $233,669,297 -$67,552,879 $1.63 95
2025 Q2 165,944,662 $378,376,899 +$9,844,394 $2.28 93
2025 Q1 168,007,060 $260,819,521 -$3,531,773 $1.55 93
2024 Q4 168,335,372 $395,090,875 -$37,054,930 $2.35 107
2024 Q3 178,602,235 $648,320,594 +$2,536,180 $3.63 97
2024 Q2 178,106,548 $619,765,055 -$54,511,638 $3.48 106
2024 Q1 175,580,707 $1,120,176,501 +$380,385,653 $6.38 114
2023 Q4 115,868,017 $746,230,557 +$30,259,044 $6.44 97
2023 Q3 110,707,409 $257,962,960 +$2,926,164 $2.33 67
2023 Q2 109,330,876 $260,181,467 +$12,434,850 $2.38 67
2023 Q1 105,962,470 $194,950,415 -$3,026,243 $1.84 64
2022 Q4 107,371,378 $203,976,112 +$109,842,474 $1.90 69
2022 Q3 49,366,337 $105,661,961 -$3,352,319 $2.14 62
2022 Q2 50,829,136 $143,849,865 -$7,115,566 $2.83 57
2022 Q1 45,661,103 $190,513,250 -$17,791,387 $4.17 60
2021 Q4 52,463,220 $272,271,730 +$101,855,863 $5.19 69
2021 Q3 25,076,258 $164,226,984 -$2,136,433 $6.55 55
2021 Q2 25,378,541 $169,575,110 +$23,313,452 $6.64 64
2021 Q1 22,400,702 $128,321,739 +$53,655,759 $5.73 58
2020 Q4 12,635,638 $112,960,120 +$962,285 $8.94 46
2020 Q3 12,386,365 $143,379,095 -$24,849,875 $11.64 44
2020 Q2 14,328,662 $229,696,396 -$16,435,312 $16.03 48
2020 Q1 15,977,491 $96,357,056 +$6,942,585 $5.99 50
2019 Q4 13,423,917 $177,195,289 +$748,992 $13.20 54
2019 Q3 13,444,843 $166,969,346 -$100,503,433 $12.42 42
2019 Q2 21,383,578 $344,232,698 +$52,450,982 $16.10 45
2019 Q1 18,088,058 $569,233,000 +$34,027,507 $31.47 32
2018 Q4 16,988,795 $557,884,000 -$24,061,507 $32.84 36
2018 Q3 17,853,077 $546,310,000 +$275,258,001 $30.66 39
2018 Q2 9,009,943 $241,253,000 +$237,222,000 $26.79 49
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .